S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs

Antiviral Research

Volumn 53, Issue 2, 2002, Pages 143-152

  Gröschel, B ^a   Cinatl, J ^b   Périgaud, C ^c   Gosselin, G ^c   Imbach, J ^c   Doerr, H W ^a   Cinatl Jr , J ^a  

^a Institute of Medical Virology   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c CNRS   (France)

Author keywords

Ara C; AZT; Cellular resistance; HIV 1; Mononucleotide; Prodrug

Indexed keywords

CYTARABINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; LAMIVUDINE; MESSENGER RNA; NUCLEOTIDE DERIVATIVE; PRODRUG; THYMIDINE DERIVATIVE; THYMIDINE KINASE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL DIVISION; CELL LINE; CYTARABINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES; THYMIDINE; THYMIDINE KINASE; VIRUS REPLICATION;

ARA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036144554     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00205-4     Document Type: Article

References (40)

1. Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine
2. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase
3. Thymidine and 3′-azido-3′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages
4. Pharmacological issues relating to viral resistance
5. The inhibitory effect of ddC on human immunodeficiency virus replication diminishes in cells that are chronically exposed to the drug
6. Cytidine analogs
7. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
8. Decreased anti-human immunodeficiency virus type-1 activities of 2′,3′-dideoxynucleoside analogs in Molt-4 cell sublines resistant to 2′,3′-dideoxynucleoside analogs
9. HIV resistance to AZT in MOLT-4/8 cells is associated with the lack of AZT phosphorylation and is bypassed by AZT-monophosphate SATE-prodrugs
10. Zidovudine induces the expression of cellular resistance affecting its antiviral activity
11. Studies on drug resistance. II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-β-d-arabinofuranosylcytosine
12. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside
13. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase
14. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells
15. Deutsche AIDS-Gesellschaft (DAIG). Oesterreichische AIDS-Gesellschaft (OAG). German-Austrian guidelines for antiretroviral therapy in HIV infection
16. Increase of the anti-HIV activity of D4T in human T-cell culture by the use of the SATE pronucleotide approach
17. Viral and cellular factors for resistance against antiretroviral agents
18. ddC- and 3TC-bis(SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV-1 associated with cytidine kinase deficiency
19. Effects of cycloSal-d4TMP derivatives in H9 cells with induced AZT resistance phenotype
20. Activity of thymidine kinase 1 in PBMCs of HIV-1 infected patients: Novel therapy marker
21. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
22. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: Implications for zidovudine metabolism
23. Design of anti-HIV compounds: From nucleoside to nucleoside 5′-triphosphate analogs. Problems and perspectives
24. HIV with reduced sensitivity to zidovudine (AZT) isolated during prologned therapy
25. The bottleneck in AZT activation
26. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate
27. 2′,3′-Dideoxycytidine metabolism in a new drug-resistant cell line
28. Antiretroviral resistance during successful therapy of HIV type 1 infection
29. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides
30. Novel approaches for designing 5′-O-ester prodrugs of 3′-azido-2′, 3′-dideoxythymidine (AZT)
31. Rational design for cytosolic delivery of nucleoside monophosphates: 'SATE' and 'DTE' as enzyme-labile transient phosphate protecting groups
32. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine
33. Comparison of cytotoxicity of mononucleoside phosphotriester derivatives bearing biolabile phosphate protecting groups in normal human bone marrow progenitor cells
34. Minireview: From the pronucleotide concept to the SATE phosphate protecting groups
35. The SATE pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-HBV activity of bis(SATE)phosphotriester derivatives of acyclovir
36. Anti-HIV phosphotriester nucleotides. Basis for the rational design of biolabile phosphate protection
37. A simple method of estimating fifty per cent endpoints
38. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC)
39. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides
40. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK1) gene and hypermethylation of the 5′ end of human TK gene